In view of the potential clonal restriction of CD8-positive T lymphocytes actively counteracting the tumour and its progression, we investigated whether the tumour-cell-specific expression of Her2/neu protein in ovarian carcinomas may represent a candidate target antigen of TILs, as suggested for breast cancer (Peoples et al, 1995; Goodell et al, 2008; Wiech et al, 2008) and as shown in a murine model of ovarian cancer (Yang et al, 2007). This evidence concerns the gene ERBB2 and breast carcinoma.